Cardiff Oncology Q1 2024: $67.2M cash, ONSEMBLE data show 50% ORR in bev naïve mCRC

Cardiff Oncology, Inc.

Cash and equivalents $67.2M as of March 31, 2024; projected runway into Q3 2025.
Operating expenses $11.1M, down $1.0M YoY; net cash used in ops $7.7M.
ONSEMBLE trial: bev naïve patients on onvansertib+SoC had 50% ORR vs 0% for SoC alone.
Initial readout from first-line RAS-mutated mCRC Phase 2 CRDF-004 trial expected 2H 2024.
Preclinical AACR data showed onvansertib activity in RAS wild-type mCRC, SCLC, and ovarian cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 2, 2024, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2024 .

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-020010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.